Is Pfizer's 6.9%-Yielding Dividend Still Safe?

Key Points A high-yielding payout hasn't been enough reason for investors to buy Pfizer's stock. The pharmaceutical giant's valuation has been cut in half in just three years. Investors appear to be worried about what lies ahead for the business. 10 stocks we like better than Pfizer › Healthcare giant Pfizer (NYSE: PFE) has been offering a high yield for some time. But that hasn't been enough to get investors to buy up the stock. You can see that in its sluggish share price, and also in the fact ...